Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8

使用与单克隆抗体 3F8 结合的载 SN-38 纳米粒子在表达 GD2 的神经母细胞瘤患者来源的异种移植瘤的肿瘤细胞外液中进行靶向药物分布

阅读:8
作者:Carles Monterrubio, Sonia Paco, Nagore G Olaciregui, Guillem Pascual-Pasto, Monica Vila-Ubach, Maria Cuadrado-Vilanova, M Mar Ferrandiz, Helena Castillo-Ecija, Romina Glisoni, Nataliya Kuplennik, Achim Jungbluth, Carmen de Torres, Cinzia Lavarino, N K V Cheung, Jaume Mora, Alejandro Sosnik, Angel M

Abstract

Neuroblastoma is a pediatric solid tumor with high expression of the tumor associated antigen disialoganglioside GD2. Despite initial response to induction therapy, nearly 50% of high-risk neuroblastomas recur because of chemoresistance. Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticles (NPs) surface-decorated with the anti-GD2 mouse mAb 3F8 at a mean density of seven antibody molecules per NP. The accumulation of drug-loaded NPs targeted with 3F8 versus with control antibody was monitored by microdialysis in patient-derived GD2-expressing neuroblastoma xenografts. We showed that the extent of tumor penetration by SN-38 was significantly higher in mice receiving the targeted nano-drug delivery system when compared to non-targeted system or free drug. This selective penetration of the tumor extracellular fluid translated into a strong anti-tumor effect prolonging survival of mice bearing GD2-high neuroblastomas in vivo.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。